z-logo
open-access-imgOpen Access
Anti-IL-5 treatments in severe eosinophilic asthma: real life datas
Author(s) -
Betül Özdel Öztürk,
Sevim Bavbek
Publication year - 2020
Publication title -
tuberkuloz ve toraks/tüberküloz ve toraks
Language(s) - English
Resource type - Journals
ISSN - 0494-1373
DOI - 10.5578/tt.69416
Subject(s) - asthma , medicine , eosinophilic , immunology , pathology
Randomized controlled studies have shown that anti-IL-5 treatments reduce the need for oral corticosteroids, annual asthma exacerbation and hospitalization rates, blood eosinophil count and increase FEV1 values, asthma control, and quality of life in patients with eosinophilic severe asthma. Although the number of real-life studies with anti-IL-5 is limited, there are 10 real life studies with mepolizumab, one real life study with benralizumab and one real life study with reslizumab in the current literature. Similar to randomized controlled trials, real-life studies reported that a reduction in the need for oral corticosteroids, annual asthma exacerbation and hospitalization rates, and blood eosinophil counts and increase FEV1 values, asthma control test and quality of life scores, Response criteria were defined in some of the real-life studies and although different response rates were given according to these criteria, most of the patients with severe eosinophilic asthma showed high response rates to anti-IL-5 treatments. In real-life studies evaluating the safety of anti-IL-5 treatments, the most common adverse effect is mild local injection site reaction that does not require treatment, in conclusion, real-life studies suggest that all three anti-IL-5 treatments in clinical practice are effective and well tolerated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here